Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686198 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
A Phase 2 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07686198 is a Phase 2 study that has not yet begun recruiting, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants.
The verdict
NCT07686198, a Phase 2 study, has not yet begun recruiting, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective is to compare Re-Q Pro-Longevity serum versus vehicle serum combined with Intense Pulsed Laser for the treatment of moderate to severe photodamage and crepiness on the dorsal forearms.
Interventions
- DRUG Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy
- DRUG Left Arm treated with vehicle serum and Intense Pulsed Light Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-10 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07686198
The ClinicalTrials.gov registry entry for NCT07686198 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy is the first listed.
NCT07686198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07686198 about?
NCT07686198 is a clinical study titled "Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms". The primary objective is to compare Re-Q Pro-Longevity serum versus vehicle serum combined with Intense Pulsed Laser for the treatment of moderate to severe photodamage and crepiness on the dorsal forearms.
What is the current status of trial NCT07686198?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-07-10. Estimated completion is 2027-01-30.
What interventions are being tested in trial NCT07686198?
The interventions under investigation include: Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy (DRUG), Left Arm treated with vehicle serum and Intense Pulsed Light Therapy (DRUG).
Who is sponsoring clinical trial NCT07686198?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.